# Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

> **NCT06126497** · PHASE2 · COMPLETED · sponsor: **Suven Life Sciences Limited** · enrollment: 41 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Ropanicant

## Key facts

- **NCT ID:** NCT06126497
- **Lead sponsor:** Suven Life Sciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-05
- **Primary completion:** 2024-07-19
- **Final completion:** 2024-07-19
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126497, "Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06126497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*